One of the more discussed topics in healthcare over the past decade has been the transition to a value-based system. No doubt it's a worthy goal, however the road has been a bumpy one at best. One of the toughest challenges has been getting a handle on the concept of value: how to define it, how optimize it, how to price it and what value means across the healthcare ecosystem.
While the conversation tends to take place in silos, moving to a value-based system means having conversations among all stakeholders. Bringing pharma, PBMs and payers to the same table to talk value is just one way to...
The thought of gathering massive amounts of data, from claims to EHR to molecular and making it easily accessible for drug development research once seemed impossible, as did getting at previously 'undruggable' pathways that defied the effects of even the most innovative drugs. Now, with the advent of immuno-oncology, the oncology field is poised to take advantage of these advances to enable the development of precise therapies that match the right drug to the right patient.
The recent GNS Precision Medicine Forum presented a panel of pharma industry experts leading the charge in using...
What does the future of pharma look like through the eyes of a technologist’s background? We were fortunate enough to find out at last month at our 2nd annual GNS Forum. Shahram Ebadollahi, PhD, MBA who is the Global Head of Data Science and AI at Novartis AG, joined us to share his thoughts on how to bring the promise of AI to fruition for biopharma.
“How often have pharma, insurance and provider leaders thought about the ‘organizing principles’ around healthcare?”
That’s a question posed by Greg Simon, President of the Biden Cancer Initiative, at the recent GNS Precision Medicine Forum. His answer? Not enough. That was the overarching message of his presentation to the gathered group of healthcare industry leaders.
Organizing principles, the guiding ideas used to direct a society, organization or initiative are important because they create the framework and provide a consistent direction that propels a company, entity or industry toward...
My dermatologist looked at me somberly from across her desk.
“I’m not sure we have a lot of options for you,” she said finally. “I’m very sorry.”
I was in the prime of my life with two small children and my doctor was basically handing me a death sentence. I was devastated.
I had had a mole removed a week earlier, and tests revealed it to be melanoma. The depth of the tumor on the top of my foot was just over 1 ml and at that time, 14 years ago, the prognosis for melanoma patients with tumors of that depth was not great.
Happy Fourth of July – a day we celebrate the birth of our nation. A day we recognize and applaud our country’s founders who were bold and progressive thinkers. A day to be grateful for the establishment of the United States and its founding principles which have weathered the test of time.
The path to revolution is one familiar to the pioneers of healthcare: slow to change, rife with internal disagreement and peppered by a number of fits and starts. If it sounds familiar, it should. The push for change and efficiency has been propelling new advancements in healthcare. Instead of throwing...
The FDA's role has always been to balance safety and efficacy when it comes to approving drugs, medical devices and biological products. And yet the numbers are staggering, to bring a drug to market costs on average $2.7B and takes close to a decade. So how did we get here and what does the future hold? For this blog we take a look back at how the FDA came to be, how Dr. Scott Gottlieb's tenure as FDA Commissioners modernized the FDA, and some speculations for what the future holds.
Chances are, you know of someone who suffers from multiple myeloma, non-Hodgins lymphoma or multiple-sclerosis. Despite the familiarity of those conditions, all three are considered rare-diseases by the U.S. Food and Drug Administration (FDA) because they affect less than 200,000 people in the U.S.
According to estimates by the National Institute of Health, there may be as many as 7,000 rare diseases affecting approximately 25-35 million Americans. So what do rare diseases have to do with AI?
Albert Einstein is quoted as saying, "in the middle of difficulty lies opportunity." With the surge of healthcare data we have a great opportunity healthcare in a way not seen before. But, it is well known that using flawed data produces unreliable outputs. Given the breadth and depth of data that grows daily and the power of artificial intelligence (AI) – how do we leverage both to impact how drugs are discovered and developed?
Spring is the season of renewal, growth and new beginnings. It is also the time when the healthcare community gets together at key conferences to exchange ideas, findings and results. This year is no different with three major gatherings scheduled for May and June. Discussion of oncology and artificial intelligence are high on the agendas of all three events. Here's a rundown of what to look out for.